Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Lung cancer is the leading cause of cancer worldwide with approximately 1.2 million new cases
each year. Non-small cell lung cancer (NSCLC) accounts for greater than 80% of all lung
carcinomas in Western countries. Surgical resection is the treatment of choice for patients
with early stage disease (Stage I and II), but at least 50% of these patients will relapse
locally and/or develop distant metastases. Furthermore, 70% of patients with NSCLC are
non-resectable at the time of their diagnosis due to either locally advanced or metastatic
disease. The long-term prognosis for patients with NSCLC remains poor with the overall 5-year
survival rate less than 15%. The low survival rate may be attributed to the high incidence of
unresectable disease at presentation and the inability of systemic therapy to cure metastatic
disease. There is a clear need for improvement in the treatment of NSCLC.